NCT00116922View on ClinicalTrials.gov

A Lifestyle and Combination Medication Therapy Diabetes Prevention Study

PHASE3CompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Impaired Glucose ToleranceDiabetes
Interventions
DRUG

Avandamet [Rosiglitazone 2mg/Metformin 500mg] BID

\[Rosiglitazone 2mg/ Metformin 500mg\] twice daily

Trial Locations (2)

N6G 4X8

UWO Research Park, London

M5G 1X5

Mount Sinai Hospital, Toronto

All Listed Sponsors
collaborator

University of Western Ontario, Canada

OTHER

lead

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

OTHER

NCT00116922 - A Lifestyle and Combination Medication Therapy Diabetes Prevention Study | Biotech Hunter | Biotech Hunter